Key facts
- Oorja Bio’s last known valuation is $33.5M (Jun 2025).
- It has raised $20.0M; the latest was Early Stage VC ($20.0M) in Jun 2025.
- Notable investors include Westlake Village BioPartners.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Oorja Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Oorja Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Oorja Bio
Operator of a biotechnology company intended to develop therapies for cardiopulmonary and fibrotic diseases by targeting the underlying pathophysiology and promoting cellular repair. The company offers medicines that remodel and reverse fibrotic tissue through advanced pathway-targeting approaches, enabling customers to move beyond symptom management toward long-term disease modification, improved quality of life and a new therapeutic standard of care.
- Sector
- Healthcare
- HQ
- Houston, TX, United States
- Founded
- 2023
- Employees
- 4
- Website
- oorjabio.com/
- Ownership
- Privately Held (backing)
Oorja Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Oorja Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Oorja Bio in its N-PORT filings yet. We sweep new filings monthly.